RxDoctor Payments Data

Jeffrey Stephens, MD

Ophthalmology · Edina, MNNPI 1508833138

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,360 of the $6,801 with a category attached, or 64.1%. AbbVie accounts for 64.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $4,443 and has fallen 94.0% since, to $266 in 2025. Among ophthalmology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,801in general payments, 2019–2025

Across 10 payments — averaging $680.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Alcon$2K
  • Glaukos Corporation$83

What the payments were for

  • Consulting fees$4,36064%
  • Food & beverage$5087%
  • Other$1,93328%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)2$4,393
Alcon7$2,324
Glaukos Corporation1$83

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,801 in reported general payments places this provider in the 90th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$246,086
Medicare patients
741
Services billed
1,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine53$59,671
Cyclosporine37$32,658
LumiganBimatoprost56$28,795
Latanoprost968$20,289
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$9,142
Travoprost24$7,584
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat280$6,607
Prednisolone Acetate169$6,324
Timolol Maleate318$6,053
Brimonidine Tartrate119$5,542
Brinzolamide14$4,103
MoxifloxacinMoxifloxacin Hcl138$2,548
Ketorolac Tromethamine146$2,380
Dorzolamide Hcl31$663
ErythromycinErythromycin Base32$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$4,393$88,466109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →